Sheesh.. this was a hard one! So many good nominations.
All up we've got about 20 suggestions across a wide variety of sectors, but it looks like Medical Developments International (ASX:MVP) got the most support. So, in the spirit of democracy, let's go with that.
I'll schedule our roundtable discussion for Wednesday the 24th of June to give us two weeks to dig into things.
EBR could be a candidate? Low SP, major capital raise just completed to fund commercialisation. WISE CRT implants increasing, multiple US hospital deals signed and surgeon training increasing. Lots of execution and adoption risk but one to watch
To move into voting rather than adding (as no-one's picked up $IEL that @Rick and I mentioned), to pick up on @Bear77's theme, I like the idea of focusing attention on stocks that are either "under the radar" or "beaten up", rather than one's that are on a tear- simply because I am likely to get over-enthusiastic and overpay (which I have a track record of doing quite often!)
So, of those mentioned:
Happy also to add "half votes" for $VYS and and $SKS. but the price action on both is strong.
Less keen on $RMD, $COH and $CSL because there is a lot over coverage both "out there" and "on here" (e.g. $RMD). For RMD you could run the AI on all the Strawman content and get a pretty good video already, I reckon. If these healthcare leaders are popular, then I'd go for $COH. $CSL would only make sense if we put in a big collective research effort, as it is a complex business and it would be a missed opportunity if we only had a superficial discussion.
Of course, I'll be happy whatever is selected.